We are live on ! Find out more
Commodore Capital

Commodore Capital Portfolio holdings

AUM $1.68B Turnover 31.71%
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$856M
AUM Growth
-$34.3M
Cap. Flow
+$13.7M
Cap. Flow %
1.6%
Top 10 Hldgs %
65.11%
Holding
33
New
7
Increased
9
Reduced
3
Closed
3
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$46.5M
2
MRUS icon
Merus
MRUS
+$10.4M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.3M
4
ELVN icon
Enliven Therapeutics
ELVN
+$9.32M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$6.99M

Top Sells

Rank Stock Value
1
AKRO icon
Akero Therapeutics
AKRO
+$51.7M
2
CBAY icon
Cymabay Therapeutics
CBAY
+$22.2M
3
ARWR icon
Arrowhead Research
ARWR
+$21.8M
4
NUVL icon
Nuvalent
NUVL
+$14.3M
5
KALV icon
KalVista Pharmaceuticals
KALV
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRUS icon
1
DELISTED
Merus
MRUS
$104M 12.2%
4,428,072
+428,072
+11% +$10.4M
2021 Q3
8 quarters
VERA icon
2
Vera Therapeutics
VERA
$2.16B
$74.7M 8.73%
5,450,000
– –
2023 Q1
2 quarters
XENE icon
3
Xenon Pharmaceuticals
XENE
$3.49B
$63M 7.37%
1,845,000
– –
2020 Q4
11 quarters
PCVX icon
4
Vaxcyte
PCVX
$9.5B
$56.1M 6.55%
1,100,000
+85,000
+8% +$4.19M
2022 Q4
3 quarters
COGT icon
5
Cogent Biosciences
COGT
$5.55B
$54.3M 6.34%
5,566,026
– –
2020 Q4
11 quarters
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.35B
$47.6M 5.56%
+2,075,000
New +$46.5M
2023 Q3
0 quarters
AMAM
7
DELISTED
Ambrx Biopharma Inc
AMAM
$40.5M 4.73%
3,518,556
+343,556
+11% +$4.68M
2023 Q1
2 quarters
ELVN icon
8
Enliven Therapeutics
ELVN
$3.2B
$39.6M 4.63%
2,901,816
+553,544
+24% +$9.32M
2022 Q4
3 quarters
CABA icon
9
Cabaletta Bio
CABA
$248M
$38.4M 4.49%
2,525,753
+157,567
+7% +$2.15M
2022 Q4
3 quarters
IMVT icon
10
Immunovant
IMVT
$5.97B
$38.4M 4.49%
1,000,000
+100,000
+11% +$2.26M
2022 Q4
3 quarters
NUVL icon
11
DELISTED
Nuvalent
NUVL
$38.1M 4.45%
828,778
-321,222
-28% -$14.3M
2022 Q4
3 quarters
VRDN icon
12
Viridian Therapeutics
VRDN
$2.73B
$33.7M 3.94%
2,200,000
– –
2021 Q1
10 quarters
AKRO icon
13
DELISTED
Akero Therapeutics
AKRO
$28.6M 3.34%
565,000
-1,110,000
-66% -$51.7M
2022 Q3
4 quarters
SLNO icon
14
DELISTED
Soleno Therapeutics
SLNO
$26.2M 3.06%
+887,500
New +$5.37M
2023 Q3
0 quarters
IDYA icon
15
IDEAYA Biosciences
IDYA
$3.23B
$20.9M 2.44%
775,000
– –
2023 Q2
1 quarter
CLDX icon
16
Celldex Therapeutics
CLDX
$2.37B
$19.4M 2.27%
706,665
+75,000
+12% +$2.35M
2022 Q1
6 quarters
CELC icon
17
Celcuity
CELC
$3.33B
$15.5M 1.81%
1,694,141
+250,000
+17% +$2.46M
2021 Q2
9 quarters
ALPN icon
18
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.2M 1.77%
1,325,000
– –
2022 Q3
4 quarters
ADVM icon
19
DELISTED
Adverum Biotechnologies
ADVM
$15M 1.75%
1,000,000
– –
2023 Q1
2 quarters
CRNX icon
20
DELISTED
Crinetics Pharmaceuticals
CRNX
$14.9M 1.74%
+500,000
New +$10.3M
2023 Q3
0 quarters
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.22B
$13.9M 1.63%
957,509
-40,087
-4% -$758K
2022 Q3
4 quarters
KURA icon
22
Kura Oncology
KURA
$881M
$12.8M 1.49%
1,400,000
– –
2022 Q1
6 quarters
THRD icon
23
DELISTED
Third Harmonic Bio
THRD
$10.9M 1.27%
1,700,000
+706,706
+71% +$4.32M
2022 Q3
4 quarters
DAWN icon
24
DELISTED
Day One Biopharmaceuticals
DAWN
$9.08M 1.06%
739,661
– –
2022 Q2
5 quarters
VTGN icon
25
VistaGen Therapeutics
VTGN
$7.72M
$8.25M 0.96%
+1,575,000
New +$6.99M
2023 Q3
0 quarters
1
2

Similar funds

Trustmark National Bank Trust Department
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
Clearline Capital
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Invenomic Capital Management
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Anson Funds Management
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Commodore Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Commodore Capital held 33 positions worth $856M, down 3.9% from $890M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Commodore Capital's Q3 2023 filing shows 7 new, 9 increased, 3 reduced and 3 closed positions. Its largest new stake was Rhythm Pharmaceuticals: 2,075,000 shares worth $47.6M. The largest sale was Akero Therapeutics, an estimated $51.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Commodore Capital's largest Q3 2023 buy was Rhythm Pharmaceuticals: 2,075,000 shares worth $47.6M.
  • Commodore Capital added most to Merus in Q3 2023, an estimated $10.4M increase.
  • Commodore Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $51.7M.
  • Commodore Capital fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $22.2M.
  • Commodore Capital's ten largest holdings make up 65% of its $856M portfolio in Q3 2023.
  • Commodore Capital opened 7 new positions and closed 3 in Q3 2023.
  • Commodore Capital's portfolio value fell 3.9% quarter-over-quarter to $856M.

Based on Commodore Capital's 13F filing for Q3 2023, filed 14 Nov 2023.